Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Blumenthal

Showing results (621-630 of 650) with videos related to

Pageof 65
Sort By:
Ecology Letters|January 26, 2013
Life-history constraints in grassland plant species: a growth-defence trade-off is the normEric M Lind, Elizabeth Borer, Eric Seabloom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2013
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancerGideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Erik Bloomquist, Shenghui Tang, et al.
Nature Plants|February 10, 2019
Globally consistent influences of seasonal precipitation limit grassland biomass response to elevated CO<sub>2</sub>Mark J Hovenden, Sebastian Leuzinger, Paul C D Newton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2018
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerHarpreet Singh, Amanda J Walker, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2018
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid LeukemiaAviva C Krauss, Xin Gao, Liang Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 13, 2016
Clinician Perspectives on Current Issues in Lung Cancer Drug DevelopmentSaiama N Waqar, Philip D Bonomi, Ramaswamy Govindan, et al.
JAMA Oncology|November 22, 2019
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerSundeep Agrawal, Naomi B Haas, Mohammadhadi Bagheri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.
Ecology|July 18, 2013
Do invasive species perform better in their new ranges?John D Parker, Mark E Torchin, Ruth A Hufbauer, et al.
Pageof 65

Showing results (621-630 of 650) with videos related to

Sort By:
Pageof 65
Ecology Letters|January 26, 2013
Life-history constraints in grassland plant species: a growth-defence trade-off is the normEric M Lind, Elizabeth Borer, Eric Seabloom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2013
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancerGideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Erik Bloomquist, Shenghui Tang, et al.
Nature Plants|February 10, 2019
Globally consistent influences of seasonal precipitation limit grassland biomass response to elevated CO<sub>2</sub>Mark J Hovenden, Sebastian Leuzinger, Paul C D Newton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2018
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerHarpreet Singh, Amanda J Walker, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2018
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid LeukemiaAviva C Krauss, Xin Gao, Liang Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 13, 2016
Clinician Perspectives on Current Issues in Lung Cancer Drug DevelopmentSaiama N Waqar, Philip D Bonomi, Ramaswamy Govindan, et al.
JAMA Oncology|November 22, 2019
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerSundeep Agrawal, Naomi B Haas, Mohammadhadi Bagheri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.
Ecology|July 18, 2013
Do invasive species perform better in their new ranges?John D Parker, Mark E Torchin, Ruth A Hufbauer, et al.
Pageof 65